Skip to main content

Table 2 Discontinuations and reasons for discontinuations*

From: Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

 IFXGLMGLM-IV
Total discontinuations (n/N, %)659/890, 74.0%280/530, 65.6%71/157, 45.2%
Exposure (Total, Mean pt. yrs)2714, 3.01077, 2.0257, 1.6
Reason for discontinuation (n, %a)
 Patient withdrew consent58, 8.8%25, 8.9%4, 5.6%
 Adverse event116, 17.6%33, 11.8%10, 14.1%
 Lost to follow-up25, 3.8%28, 10.0%7, 9.9%
 Financial reasons14, 2.1%4, 1.4%0, 0.0%
 Complete response10, 1.5%4, 1.4%0, 0.0%
 Disease progression75, 11.4%14, 5.0%2, 2.8%
 Lack of response45, 6.8%67, 23.9%22, 31.0%
 Loss of response65, 9.9%46, 16.4%6, 8.5%
 Unusual lack of efficacy0, 0%1, 0.4%0, 0%
 Geographic issues24, 3.6%3, 1.1%2, 2.8%
 Patient switched to another therapy32, 4.9%15, 5.4%9, 12.7%
 Did not meet entry criteria1, 0.2%0, 0.0%0, 0.0%
 Other191, 29.0%40, 14.3%8, 11.3%
 Missing3, 0.5%0, 0%1, 1.4%
  1. aProportions based on number of discontinued patients